Extending our previous research investigating biomarkers that are clinically important to distinguish patients with prostate cancer at risk for early relapse from patients in clinical remission [12-14], in this study, we analyzed by RT-PCR assays p503S, p504S and p510S gene markers in PB from 42 patients with treated or untreated CaP and with benign prostatic hyperplasia (BPH) (controls). Here, AMACR is linked to prostate carcinoma.